

PRESS CONFERENCE SCHEDULE

Conference on Retroviruses and Opportunistic Infections/CROI 2019

All press conferences will be held in room 400 of the Washington State Convention Center. Embargoes on research presented in CROI press conferences lift at the end of the study's presentation in either its conference session or as part of a CROI press conference, whichever is earlier. All times listed are PT.

This press conference may be viewed live at <https://zoom.us/j/755218010> or accessed by phone toll-free from the U.S. at 877 853 5247 or 877 369 0926; Webinar ID: 755 218 010. International telephone access numbers [here](#).

Monday, March 4, 3:30 – 4:30 pm

3:30 – 4:00 pm Chaired by Richard Koup, *CROI Chair and National Institute of Allergy and Infectious Diseases, Bethesda, MD, US*

WELCOME AND OVERVIEW OF CROI 2019

Richard Koup, CROI Chair and National Institute of Allergy and Infectious Diseases, Bethesda, MD, US

Elaine Abrams, CROI Vice Chair and Columbia University, New York, NY, US

Sharon Hillier, CROI Vice Chair and University of Pittsburgh, Pittsburgh, PA, US

ENDING THE HIV EPIDEMIC: A PLAN FOR THE UNITED STATES

Anthony Fauci, National Institute of Allergy and Infectious Diseases, Bethesda, MD, US

4:00 – 4:30 PM Chaired by Susan Buchbinder, *University of California San Francisco, CA, US*

ORAL ABSTRACT SESSION 5 – STRANGE BEDFELLOWS: STIS, CONTRACEPTION, AND TRIALS OF HIV TESTING

(PRESENTED TUESDAY, MARCH 5 10:00 AM - 12:00 PM; EMBARGO ON THESE STUDIES LIFTS MONDAY, MARCH 4, AT THE CONCLUSION OF THEIR PRESS CONFERENCE PRESENTATION)

47. Incident Syphilis Rates and Predictors in US Women with HIV, 2005-2016

Jodie Dionne-Odom, University of Alabama at Birmingham, Birmingham, AL, US

53 LB. Point-of-Care Viral Load Testing Improves HIV Viral Suppression and Retention in Care

Paul Drain, University of Washington, Seattle, WA, US

ORAL ABSTRACT SESSION 9 – TESTING, VIRAL SUPPRESSION, AND IMPACT

(PRESENTED WEDNESDAY, MARCH 6 10:00 AM - 12:00 PM; EMBARGO ON THESE STUDIES LIFTS MONDAY, MARCH 4, AT THE CONCLUSION OF THEIR PRESS CONFERENCE PRESENTATION)

92 LB. Impact of Universal Testing and Treatment in Zambia and South Africa: HPTN071 (POPART)

Richard Hayes, London School of Hygiene & Tropical Medicine, London, UK

93. A Randomized Trial on Index HIV Self-Testing for Partners of ART Clients in Malawi

Kathryn Dovel, University of California Los Angeles, Los Angeles, CA, US

PRESS CONFERENCE SCHEDULE

Conference on Retroviruses and Opportunistic Infections/CROI 2019

All press conferences will be held in room 400 of the Washington State Convention Center. Embargoes on research presented in CROI press conferences lift at the end of the study's presentation in either its conference session or as part of a CROI press conference, whichever is earlier. All times listed are PT.

This press conference may be viewed live at <https://zoom.us/j/307472395> or accessed by phone toll-free from the U.S. at 877 853 5247 or 877 369 0926; Webinar ID: 307 472 395. International telephone access numbers [here](#).

Tuesday, March 5, 12:15 – 1:30 pm

12:15 – 12:40 PM Chaired by John Mellors, *University of Pittsburgh School of Medicine, Pittsburgh, PA, US*

ORAL ABSTRACT SESSION 2 – STRATEGIES FOR HIV CURE
(PRESENTED TUESDAY, MARCH 5, 10:00 AM - 12:00 PM)

24. Ex Vivo and In Vivo Editing of the SIV Genome in Nonhuman Primates by CRISPR-CAS9

Tricia Burdo, Temple University, Philadelphia, PA, US

25. Delayed Viral Rebound During ATI After Infusion of CCR5 ZFN-Treated CD4 T Cells
Pablo Tebas, University of Pennsylvania, Philadelphia, PA, US

26. Multidose IV Romidepsin: No Increased HIV-1 Expression in Persons on ART, ACTG A5315

Deborah McMahon, University of Pittsburgh, Pittsburgh, PA, US

29 LB. Sustained HIV-1 Remission Following Homozygous CCR5 Delta32 Allogenic HSCT
Ravindra Gupta, University College London, London, UK

12:40– 1:05 PM Chaired by Elaine Abrams, *Columbia University, New York, NY, US*

ORAL ABSTRACT SESSION 4 – CRITICAL ISSUES IN MATERNAL AND PEDIATRIC HEALTH
(PRESENTED TUESDAY, MARCH 5, 10:00 AM - 12:00 PM)

39 LB. Randomized Trial of Raltegravir-ART vs. Efavirenz-ART When Initiated During Pregnancy

Mark Mirochnick, Boston University, Boston, MA, US

40 LB. RCT of Dolutegravir vs. Efavirenz-based Therapy Initiated in Late Pregnancy: DOLPHIN-2

Saye Khoo, University of Liverpool, Liverpool, UK

42. Impact of Improved Nutrition/Sanitation on Neurodevelopment of HIV-exposed Children

Robert Ntozini, Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe

45. Safety & Pharmacokinetics of Monoclonal Antibody, VRC01LS, in HIV-exposed Newborns

Elizabeth McFarland, University of Colorado Anschutz Medical Campus, Aurora, CO, US

1:05– 1:30 PM Chaired by Judith Currier, *University of California Los Angeles, CA, US*

ORAL ABSTRACT SESSION 3 – NONCOMMUNICABLE DISEASES IN TREATED HIV
(PRESENTED TUESDAY, MARCH 5, 10:00 AM - 12:00 PM)

31. COPD and the Risk for Myocardial Infarction by Type in People Living with HIV
Kristina Crothers, University of Washington, Seattle, WA, US

(more)

32. HIV Post SCD Study: 80% Higher Rate of Autopsy-Defined Sudden Arrhythmic Death in HIV

Zian Tseng, University of California San Francisco, San Francisco, CA, US

33. Sudden Cardiac Death Among HIV-Infected and -Uninfected Veterans

Matthew Freiberg, Vanderbilt University, Nashville, TN, US

PRESS CONFERENCE SCHEDULE

Conference on Retroviruses and Opportunistic Infections/CROI 2019

All press conferences will be held in room 400 of the Washington State Convention Center. Embargoes on research presented in CROI press conferences lift at the end of the study's presentation in either its conference session or as part of a CROI press conference, whichever is earlier. All times listed are PT.

This press conference may be viewed live at <https://zoom.us/j/924539284> or accessed by phone toll-free from the U.S. at 877 853 5247 or 877 369 0926; Webinar ID: 924 539 284. International telephone access numbers [here](#).

45 **Wednesday, March 6, 12:15 – 1:25 pm**

12:15 – 12:35 PM Chaired by Constance Benson, *University of California at San Diego, CA, US*

ORAL ABSTRACT SESSION 7 – TB: FROM CONTACT TO CURE AND BEYOND (PRESENTED WEDNESDAY, MARCH 6, 10:00 AM - 12:00 PM)

77. IPT and Pregnancy Outcomes in HIV-positive Women, the Tshepiso Cohort
Nicole Salazar-Austin, Johns Hopkins University School of Medicine, Baltimore, MD, US

80 LB. Safety & PK of Weekly Rifapentine/Isoniazid (3HP) in Adults with HIV on Dolutegravir
Kelly Dooley, Johns Hopkins University School of Medicine, Baltimore, MD, US

84 LB. QT Effects of Bedaquiline, Delamanid or Both in MDR-TB Patients: The DELIBERATE Trial
Gary Maartens, University of Cape Town, Cape Town, South Africa

12:35 – 1:00 PM Chaired by Jüergen Rockstroh, *University of Bonn, Germany*

ORAL ABSTRACT SESSION 8 – HEPATITIS C: NOW YOU SEE ME; SOON YOU WON'T (PRESENTED WEDNESDAY, MARCH 6, 10:00 AM - 12:00 PM)

85. Fall in HCV Incidence in HIV+ MSM in London Following Wider Access to DAA Therapy
Lucy Garvey, Imperial College Healthcare NHS Trust, London, UK

86. HCV Reinfection Among HIV-infected MSM in New York City
Daniel Fierer, Icahn School of Medicine at Mt Sinai, New York, NY, US

87. A Phase 1 Study of Ledipasvir/Sofosbuvir in Pregnant Women with Hepatitis C Virus
Catherine Chappell, Magee–Womens Research Institute, Pittsburgh, PA, US

88. Incident Diabetes and Glucose Control After HCV Treatment with DAAs in Erchives
Adeel Butt, VA Pittsburgh Healthcare System, Pittsburgh, PA, US

1:00 – 1:25 PM Chaired by Sharon Hillier, *Univ of Pittsburgh, PA, US*

ORAL ABSTRACT SESSION 10 – NEW OPTIONS AND OPPORTUNITIES IN PREP (PRESENTED WEDNESDAY, MARCH 6, 10:00 AM - 12:00 PM)

101. Protection Against Vaginal SHIV Infection with an Insert Containing TAF and EVG
Charles Dobard, CDC, Atlanta, GA, US

102. Moderate Efficacy of Oral Single-Agent TAF Against Vaginal SHIV Infection in Macaques
Ivana Massud, CDC, Atlanta, GA, US

(more)

104 LB. The Phase 3 Discover Study: Daily F/TAF or F/TDF for HIV Pre-Exposure Prophylaxis

Charles Hare, University of California San Francisco, San Francisco, CA, US

106. Persistence with HIV Pre-Exposure Prophylaxis in the United States, 2012-2016

Ya-Lin Huang, CDC, Atlanta, GA, US

PRESS CONFERENCE SCHEDULE

Conference on Retroviruses and Opportunistic Infections/CROI 2019

All press conferences will be held in room 400 of the Washington State Convention Center. Embargoes on research presented in CROI press conferences lift at the end of the study's presentation in either its conference session or as part of a CROI press conference, whichever is earlier. All times listed are PT.

This press conference may be viewed live at <https://zoom.us/j/343696549> or accessed by phone toll-free from the U.S. at 877 853 5247 or 877 369 0926; Webinar ID: 343 696 549. International telephone access numbers [here](#).

Thursday, March 7, 12:15 – 1:15 pm

12:15 – 12:50 PM Chaired by Joseph Eron, *University of North Carolina Chapel Hill, NC, US*

ORAL ABSTRACT SESSION 13 – ANTIRETROVIRAL CLINICAL TRIALS AND RESISTANCE
(PRESENTED THURSDAY, MARCH 7, 10:00 AM - 12:00 PM)

139. Long-acting Cabotegravir + Rilpivirine as Maintenance Therapy: ATLAS Week 48 Results

Susan Swindells, University of Nebraska Medical Center, Omaha, NE, US

140 LB. Long-acting Cabotegravir + Rilpivirine for HIV Maintenance: FLAIR Week 48 Results

Chloe Orkin, Queen Mary University of London, London, UK

141. Safety and PK of Subcutaneous GS-6027, a Novel HIV-1 CAPSID Inhibitor

Jennifer Sager, Gilead Sciences, Inc, Foster City, CA, US

142. A Phase IIA Study of Novel Maturation Inhibitor GSK2838232 in HIV Patients

Edwin DeJesus, Orlando Immunology Center, Orlando, FL, US

12:50 – 1:15 PM Chaired by Kevin De Cock, *CDC, Nairobi, Kenya*

ORAL ABSTRACT SESSION 14 – PERSISTENT CHALLENGES WITH ANTIRETROVIRAL THERAPY
(PRESENTED THURSDAY, MARCH 7, 10:00 AM - 12:00 PM)

146. Mortality Reduction in Western Kenya During Scale-up of HIV Treatment, 2011-2016

Emily Zielinski-Gutierrez, CDC, Atlanta, GA, US

147. Opioid Overdose Deaths Among Persons with HIV Infection, United States, 2011-2015

Karin Bosh, CDC, Atlanta, GA, US

148. Early Mortality in HIV-infected Patients Initiating ART Without a Pretherapy CD4

Kombatende Sikombe, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia